A Phase I Dose-Escalation Study of Bgb-A317, an Anti-Programmed Death-1 (Pd-1) Mab in Patients with Advanced Solid Tumors
Journal of clinical oncology(2016)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined